Stock of the Day

Abbott Laboratories (ABT)

$100.71

+$1.88 (+1.9%)

Market Cap: $172.14B

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

• The current stock price is around $120, reflecting strong market confidence in Abbott Laboratories' growth potential.
• Abbott Laboratories has a robust payout ratio of 70.59%, indicating a commitment to returning value to shareholders through dividends.
• The company is a leader in diagnostics, with its latest Alinity family of instruments providing advanced testing solutions for infectious diseases and chronic conditions, which is crucial in today's healthcare landscape.
• Abbott Laboratories has a diverse portfolio across multiple healthcare sectors, including medical devices and nutritionals, which helps mitigate risks associated with market fluctuations.
• Recent innovations in their product lines have positioned Abbott Laboratories favorably in the competitive healthcare market, enhancing its growth prospects.

Abbott Laboratories Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

• Despite its strong market position, Abbott Laboratories faces intense competition in the healthcare sector, which could impact its market share and profitability.
• The company's high payout ratio may raise concerns about its ability to reinvest in growth opportunities, potentially limiting future expansion.
• Regulatory challenges in the healthcare industry can lead to delays in product approvals, affecting Abbott Laboratories' ability to launch new products timely.
• Market volatility can impact stock performance, and recent economic uncertainties may pose risks to Abbott Laboratories' financial stability.
• Investors should be cautious of potential supply chain disruptions that could affect the availability of Abbott Laboratories' products, impacting sales and revenue.

Recent News

• Abbott: Bear Trap Over, With Richer Return Prospects (seekingalpha.com)
• Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript (benzinga.com)
• Abbott, up 11%, strikes three-month high after boosting 2026 profit outlook (msn.com)
• Abbott investigates two separate cyber incidents, says no operations affected (reuters.com)
• ABT Q2 Earnings Call Flags Stronger Second-Half Setup (finance.yahoo.com)
• Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC Says (finance.yahoo.com)
• These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results (benzinga.com)
• Abbott To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Friday (benzinga.com)
• Abbott Laboratories: Pick Up This Dividend King Deal Now (seekingalpha.com)
• US Stock Market Today: S&P 500 Futures Dip On Tariff And Energy Cost Worries (finance.yahoo.com)